MetaCap

Keros Therapeutics Inc. (KROS)

NASDAQ: KROSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

11.08-0.31 (-2.72%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KROS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$217.44M
EPS (TTM)
-$2.32
52-week range
8.98 – 22.55
Day range
11.04 – 11.59
Volume / Avg
208.69K / 196.50K
Beta
—

52-week range

$8.98$22.55

KROS stock today

Shares of Keros Therapeutics (KROS) finished lower on Nov 20 at $11.08, a drop of 2.72% or $0.31 per share, versus the S&P 500's 3.70% decline. Shares are 50.9% below their 52-week high of $22.55, set on Dec 8, 2025 and 23.4% above the 52-week low of $8.98, near the bottom of the past year's range. KROS is down 45.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.3%.

Keros Therapeutics has posted a net loss over the last twelve months (EPS of -$2.32), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Keros Therapeutics

Company profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jasbir S. Seehra Ph.D.
Headquarters
Lexington, MA
Employees
87
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Keros Therapeutics generated $243.9 million in revenue, up 0.0% from fiscal 2024. Net income was $87.0 million, for a net margin of 35.7% versus a median of -50805.7% in the prior 5 years. Operating margin was 27.7%.

Keros Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$243.86M$0$151.00K$0$20.10M
Growth—-100.00%—-100.00%—
Net income$87.01M$-187.35M$-152.99M$-104.68M$-58.74M
EPS (diluted)$2.30$-5.00$-5.20$-4.15$-2.52

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$19.83+78.97%

  • Strong buy 0
  • Buy 4
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $16.00High $25.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.70 vs $-0.96
Surprise
+172.92%

KROS news

All KROS news

Keros Therapeutics peers

Health Care sector
KROS peer companies
CompanyPrice% ChgMarket capCompare
RCKTRocket Pharmaceuticals Inc.1.95-7.58%$217.74Mvs KROS
PYXSPyxis Oncology Inc.1.81+7.74%$216.49Mvs KROS
IMRXImmuneering Corporation Class A3.38-2.03%$218.90Mvs KROS
ARCTArcturus Therapeutics Holdings Inc.7.45-1.97%$214.73Mvs KROS
ENTAEnanta Pharmaceuticals Inc.7.62-4.51%$222.19Mvs KROS
CYPHCypherpunk Technologies Inc.1.41-18.02%$210.15Mvs KROS
VNDAVanda Pharmaceuticals Inc.3.45-6.13%$208.32Mvs KROS
FTHFaeth Therapeutics Inc.7.88-9.32%$203.65Mvs KROS

Indexes, lists and sector

Keros Therapeutics stock FAQ

What is Keros Therapeutics's stock price today?

KROS last traded at $11.08 as of Nov 20, 4:00 PM EST, down 2.72% on the day. Prices are delayed at least 15 minutes.

Who is Keros Therapeutics's CEO?

Dr. Jasbir S. Seehra Ph.D. is the chief executive officer of Keros Therapeutics Inc., which has about 87 employees.

What is the KROS 52-week high?

The 52-week high for KROS is $22.55 and the 52-week low is $8.98. The stock is currently 50.9% below its high.

Compare KROS